The Russian government plans to stimulate the level of competition during public procurements of drugs for the domestic market, that will take place through the splitting of purchases and the introduction of limits on the volume of lots during state tenders.
The government plans implementation of these measures will attract producers of small and medium size to participate state tenders and will contribute to their de-centralization. That will also stimulate the level of competition.
In the meantime, these plans have already been opposed by some senior officials of the Russian Ministry of Health, according to which centralized purchases of drugs usually ensures significant savings to the state during public procurements.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze